Acetyl-TP53 (K382) Antibody

What is the functional significance of p53 acetylation at lysine 382?

p53 acetylation at lysine 382 (K382) represents a critical post-translational modification that regulates p53's tumor suppressor functions. This specific acetylation enhances p53's DNA binding affinity, stability, and transcriptional activity. Research demonstrates that K382 acetylation occurs following cellular stress, particularly DNA damage, and contributes to cell fate decisions by modulating the expression of genes involved in cell cycle arrest, DNA repair, and apoptosis .

How does Acetyl-TP53 (K382) Antibody differ from other p53 antibodies?

Acetyl-TP53 (K382) Antibody specifically recognizes p53 protein only when acetylated at lysine 382, unlike general p53 antibodies that detect total p53 protein regardless of post-translational modifications. This specificity allows researchers to investigate the acetylation status of p53 at a particular residue, providing insights into p53 activation under various experimental conditions .

The site-specific nature of this antibody enables the differential analysis of p53 regulatory mechanisms, as different lysine residues on p53 (K320, K373, K381, K382) can be acetylated by distinct acetyltransferases and may trigger different downstream effects . Using Acetyl-TP53 (K382) Antibody in conjunction with antibodies targeting other modifications (phosphorylation at S15, S20, or acetylation at other lysine residues) provides a comprehensive view of p53's activation state and potential functional outcomes in response to various cellular stresses.

What are the primary applications for Acetyl-TP53 (K382) Antibody in cancer research?

Acetyl-TP53 (K382) Antibody serves as a valuable tool in cancer research across multiple experimental approaches:

• Detection of p53 activation status: The antibody allows researchers to monitor p53 acetylation at K382 following treatment with DNA-damaging agents, histone deacetylase inhibitors (like depsipeptide), or other anticancer compounds, providing insights into the mechanisms of drug action .

• Immunohistochemistry analysis: As demonstrated in lung cancer tissue studies, the antibody can be used to assess p53 acetylation levels in patient samples, potentially serving as a biomarker for tumor classification or prognosis .

• Mechanistic studies: The antibody facilitates investigation of p53 regulation through acetylation/deacetylation processes and subsequent transcriptional activities that influence cancer cell survival, proliferation, and response to therapy .

• Drug development research: By measuring changes in p53 K382 acetylation, researchers can evaluate the efficacy of drugs targeting histone deacetylases (HDACs) or histone acetyltransferases (HATs) that modify p53 function .

These applications make Acetyl-TP53 (K382) Antibody an essential reagent for understanding p53 biology in cancer contexts and developing targeted therapeutic strategies.

What are the optimal conditions for using Acetyl-TP53 (K382) Antibody in Western blotting?

For optimal Western blotting results with Acetyl-TP53 (K382) Antibody, researchers should adhere to the following protocol:

Sample Preparation:

• Induce p53 acetylation in experimental samples using appropriate stimuli (e.g., DNA-damaging agents like doxorubicin, HDAC inhibitors like trichostatin A)

• Lyse cells in a buffer containing protease inhibitors and deacetylase inhibitors to preserve acetylation status

• Determine protein concentration and load 20-50 μg of total protein per lane

Western Blotting Protocol:

• Separate proteins on 10% SDS-PAGE gels

• Transfer to PVDF membrane (preferred over nitrocellulose for acetylated proteins)

• Block with 5% non-fat milk or 5% BSA in TBST for 1 hour at room temperature

• Incubate with Acetyl-TP53 (K382) Antibody at recommended dilution (typically 1:1000) overnight at 4°C

• Wash 3-5 times with TBST

• Incubate with appropriate HRP-conjugated secondary antibody

• Develop using enhanced chemiluminescence

Controls and Validation:

• Positive control: Lysates from cells treated with doxorubicin and trichostatin A

• Negative control: Untreated cell lysates or lysates treated with deacetylase enzymes

• Loading control: GAPDH or other housekeeping proteins

The acetylated p53 (K382) band should be detected at approximately 53 kDa. For quantitative analysis, normalization to total p53 levels is recommended to distinguish between changes in acetylation versus changes in total p53 expression.

How can I optimize immunofluorescence staining protocols using Acetyl-TP53 (K382) Antibody?

Successful immunofluorescence staining with Acetyl-TP53 (K382) Antibody requires careful attention to fixation, permeabilization, and antibody incubation conditions:

Protocol Optimization:

• Fixation and Permeabilization:

  • Fix cells with 4% paraformaldehyde for 15 minutes at room temperature

  • Permeabilize with 0.2% Triton X-100 in PBS for 10 minutes

  • For enhanced nuclear antigen detection, consider methanol fixation (-20°C for 10 minutes)

• Blocking and Antibody Incubation:

  • Block with 5% normal serum (from the species of secondary antibody origin) for 1 hour

  • Incubate with Acetyl-TP53 (K382) Antibody at 3-5 μg/mL for 3 hours at room temperature or overnight at 4°C

  • Use fluorophore-conjugated secondary antibody (e.g., NorthernLights 557-conjugated Anti-Rabbit/Mouse IgG)

  • Counterstain nuclei with DAPI

• Signal Enhancement Strategies:

  • Consider tyramide signal amplification for low-abundance targets

  • Use antigen retrieval methods if working with fixed tissues

  • Test multiple antibody concentrations to determine optimal signal-to-noise ratio

Validation Approaches:

• Include positive controls (cells treated with HDAC inhibitors like trichostatin A plus DNA-damaging agents like doxorubicin)

• Include negative controls (untreated cells or p53-null cells)

• Use siRNA knockdown of p53 or HATs to confirm specificity

Acetylated p53 (K382) typically shows nuclear localization with punctate staining pattern. When optimized, this staining can reveal important information about p53 activation status and subcellular distribution in response to various experimental conditions or in pathological samples.

What are the best induction conditions to study p53 acetylation at K382?

To effectively study p53 acetylation at K382, researchers should consider the following induction conditions that have been experimentally validated:

Induction Methods Table:

Cell Type Considerations:

• HCT116 and other colorectal cancer cells often show robust p53 acetylation responses

• HeLa cells require combined treatment (e.g., doxorubicin + TSA) for optimal results

• Neuronal cells exhibit distinct acetylation patterns and functional outcomes compared to other cell types

• Primary cells may require lower drug concentrations to avoid toxicity while still inducing acetylation

Monitoring Kinetics:
For comprehensive analysis, researchers should perform time-course experiments to capture both the rise and potential decline of K382 acetylation following treatment. Peak acetylation typically occurs between 6-24 hours post-treatment, depending on the inducing agent and cell type.

How does p53 acetylation at K382 functionally interact with other post-translational modifications of p53?

p53 acetylation at K382 operates within a complex network of post-translational modifications (PTMs) that collectively determine p53's function. Understanding these interactions is crucial for interpreting experimental results:

Key PTM Interactions with K382 Acetylation:

When investigating K382 acetylation, researchers should consider employing a panel of modification-specific antibodies to capture the full PTM landscape of p53, as the functional outcome depends on the combination of modifications rather than any single PTM in isolation.

What are the methodological approaches to study the relationship between K382 acetylation and p53 DNA binding activity?

Investigating the relationship between p53 K382 acetylation and DNA binding activity requires specialized techniques that assess both the modification status and functional outcomes:

Chromatin Immunoprecipitation (ChIP) Approaches:

• Standard ChIP Protocol:

  • Use Acetyl-TP53 (K382) Antibody to immunoprecipitate acetylated p53 bound to chromatin

  • Analyze immunoprecipitated DNA by qPCR targeting p53 response elements in genes of interest (p21, PUMA, BAX, MDM2)

  • Compare binding profiles of acetylated p53 versus total p53 to identify preferential binding sites

• Sequential ChIP (Re-ChIP):

  • First immunoprecipitate with total p53 antibody, then re-immunoprecipitate with Acetyl-TP53 (K382) Antibody

  • This approach reveals what proportion of p53 bound to specific promoters is acetylated at K382

  • Particularly useful for establishing correlation between acetylation status and target gene selectivity

• ChIP-seq Analysis:

  • Combine ChIP with next-generation sequencing to generate genome-wide binding profiles

  • Compare binding patterns of acetylated versus non-acetylated p53

  • Bioinformatic analysis can reveal motif preferences and co-factor requirements

In Vitro DNA Binding Assays:

• Electrophoretic Mobility Shift Assay (EMSA):

  • Prepare nuclear extracts from cells with induced p53 K382 acetylation

  • Incubate with labeled oligonucleotides containing p53 binding sites

  • Include Acetyl-TP53 (K382) Antibody for supershift assay to confirm identity

  • Compare binding affinity of acetylated versus non-acetylated p53

• DNA-Protein Interaction ELISA:

  • Immobilize p53 response element oligonucleotides on plates

  • Add nuclear extracts containing p53

  • Detect bound p53 using either total p53 or Acetyl-TP53 (K382) Antibody

  • Quantify differences in binding efficiency

These methodological approaches, when used in combination, provide robust evidence for how K382 acetylation affects p53's ability to recognize and bind specific DNA sequences, ultimately influencing its transcriptional program and cellular function.

How can I distinguish between the effects of different acetyltransferases on p53 K382 acetylation in experimental systems?

Distinguishing between the contributions of different acetyltransferases to p53 K382 acetylation requires systematic approaches combining genetic, pharmacological, and biochemical methods:

Experimental Strategies:

• Genetic Manipulation Approaches:

  • siRNA or shRNA-mediated knockdown of specific acetyltransferases (p300, CBP, PCAF)

  • CRISPR-Cas9 knockout cell lines for each acetyltransferase

  • Compare K382 acetylation levels by Western blotting or immunofluorescence after stress induction

  • Rescue experiments with wild-type versus catalytically inactive acetyltransferase constructs

• Pharmacological Inhibition:

  • Utilize selective inhibitors targeting different acetyltransferases:

    • C646 (p300/CBP inhibitor)

    • Garcinol (p300 and PCAF inhibitor)

    • Curcumin (p300/CBP inhibitor)

  • Determine dose-dependent effects on K382 acetylation

  • Compare temporal dynamics of inhibition with different compounds

• Co-immunoprecipitation Studies:

  • Immunoprecipitate p53 and blot for associated acetyltransferases

  • Reverse approach: immunoprecipitate acetyltransferases and blot for p53

  • Assess changes in interactions following stress induction

  • Compare wild-type p53 with lysine-to-arginine mutants (K382R) to confirm specificity

Comparative Analysis Table:

Based on experimental evidence, p300 appears to be the primary acetyltransferase responsible for K382 acetylation, particularly following treatment with HDAC inhibitors like depsipeptide . The recruitment of p300, but not CBP or PCAF, to the p53 C-terminus correlates with K382 acetylation and subsequent p21 promoter activation.

What are common issues when detecting acetylated p53 at K382 in experimental samples?

Researchers frequently encounter several technical challenges when detecting acetylated p53 at K382. Understanding these issues and implementing appropriate solutions is crucial for successful experiments:

Challenge 1: Low Signal Intensity

• Causes: Insufficient p53 stabilization, rapid deacetylation, low antibody sensitivity

• Solutions:

  • Combine DNA damage agents with HDAC inhibitors to maximize acetylation signal

  • Include deacetylase inhibitors (sodium butyrate, trichostatin A) in lysis buffers

  • Optimize antibody concentration and incubation conditions

  • Consider signal amplification techniques for immunohistochemistry/immunofluorescence

Challenge 2: High Background or Non-specific Signals

• Causes: Cross-reactivity with other acetylated proteins, insufficient blocking, high antibody concentration

• Solutions:

  • Validate antibody specificity using p53-null cells or K382R mutant p53 as negative controls

  • Optimize blocking conditions (try BSA instead of milk for phospho-specific antibodies)

  • Include competitors to reduce non-specific binding

  • Increase washing stringency and duration

Challenge 3: Inconsistent Results Between Experiments

• Causes: Variable p53 induction, cell density differences, inconsistent treatment conditions

• Solutions:

  • Standardize cell culture conditions (density, passage number)

  • Use internal controls for normalization

  • Develop consistent lysate preparation protocols

  • Consider using positive control lysates across experiments

Challenge 4: Discrepancies Between Detection Methods

• Causes: Different sensitivity thresholds, epitope accessibility issues

• Solutions:

  • Validate findings using multiple detection methods (Western blot, immunoprecipitation, immunofluorescence)

  • Optimize fixation and permeabilization for immunofluorescence to improve nuclear antigen detection

  • Consider native versus denaturing conditions for different applications

Maintaining careful records of experimental conditions and systematically testing variables will help establish reliable protocols for detecting acetylated p53 at K382 across different experimental systems.

How can I validate the specificity of Acetyl-TP53 (K382) Antibody in my experimental system?

Validating the specificity of Acetyl-TP53 (K382) Antibody is essential for ensuring reliable experimental results. The following comprehensive validation strategies should be implemented:

Genetic Validation Approaches:

• Negative Control Systems:

  • Test antibody in p53-null cell lines (H1299, Saos-2)

  • Compare signal in wild-type versus p53 knockdown/knockout cells

  • Express p53 mutant with lysine-to-arginine substitution at position 382 (K382R) that cannot be acetylated

• Modulation of Acetylation Status:

  • Compare antibody signal in cells treated with and without HDAC inhibitors

  • Express dominant-negative HDAC constructs to enhance acetylation

  • Treat lysates with recombinant deacetylases to remove acetylation

Biochemical Validation Methods:

• Peptide Competition Assay:

  • Pre-incubate antibody with acetylated K382 peptide before immunoblotting/immunostaining

  • Signal should be diminished or eliminated if antibody is specific

  • Non-acetylated K382 peptide should not compete for binding

• Immunoprecipitation-Mass Spectrometry:

  • Immunoprecipitate with Acetyl-TP53 (K382) Antibody

  • Analyze by mass spectrometry to confirm capture of p53 with acetylation at K382

  • Check for absence of non-specific proteins or non-acetylated p53

• Dual Antibody Approaches:

  • Sequential detection with total p53 antibody followed by Acetyl-TP53 (K382) Antibody

  • Co-localization studies in immunofluorescence applications

  • Comparison of signal ratios under conditions known to alter acetylation status

Technical Validation Controls:

• Loading and Treatment Controls:

  • Include positive control lysates from cells treated with doxorubicin and trichostatin A

  • Use separate detection of total p53 to normalize acetylation signals

  • Include GAPDH or other housekeeping proteins as loading controls

• Antibody Characteristic Assessment:

  • Test for lot-to-lot variation if using different antibody preparations

  • Determine optimal working concentration by titration

  • Assess performance across different applications (WB, IF, IHC, ChIP)

What controls should be included when studying p53 acetylation at K382 in different cell types?

When investigating p53 acetylation at K382 across different cell types, proper controls are essential to account for cell-specific variations in p53 regulation and to ensure accurate interpretation of results:

Essential Control Categories:

• Cell Type-Specific Baseline Controls:

  • Measure basal levels of total p53 and K382 acetylation in each cell type under standard culture conditions

  • Determine p53 half-life in each cell type (may affect detectable acetylation levels)

  • Assess endogenous levels of relevant HATs (p300/CBP) and HDACs that could influence acetylation status

• Induction Response Controls:

  • Compare acetylation response to standardized stimuli (doxorubicin, nutlin-3a, or HDAC inhibitors) across cell types

  • Create a dose-response curve for each cell type to identify optimal treatment conditions

  • Include time-course analysis to capture cell-specific temporal dynamics of acetylation

• Functional Outcome Controls:

  • Monitor expression of p53 target genes (p21, PUMA, BAX) in parallel with acetylation status

  • Compare cell cycle arrest versus apoptotic responses in relation to K382 acetylation levels

  • Account for cell type-specific differences in p53 transcriptional programs

Special Considerations for Different Cell Types:

Technical Normalization Controls:

• Always normalize acetylated p53 (K382) signal to total p53 levels to distinguish changes in acetylation from changes in p53 abundance

• Include loading controls appropriate for each cell type (some housekeeping genes vary across tissues)

• For acetylation induction experiments, include positive controls (TSA+doxorubicin treated samples) alongside each cell type

Understanding cell type-specific variations in p53 regulation and implementing these controls will allow for meaningful comparisons of K382 acetylation patterns and their functional significance across different cellular contexts.

How do different acetyltransferases and deacetylases regulate p53 K382 acetylation in normal versus cancer cells?

The regulation of p53 K382 acetylation by acetyltransferases and deacetylases exhibits distinct patterns in normal versus cancer cells, with significant implications for p53 function and cellular responses:

Acetyltransferase Regulation:

• p300/CBP in Normal Cells:

  • Tightly regulated activation in response to specific stresses

  • Balanced by appropriate deacetylase activity

  • Results in transient p53 acetylation and controlled cell cycle arrest

• p300/CBP in Cancer Cells:

  • Often dysregulated through mutations or expression changes

  • May show altered recruitment to p53 following DNA damage

  • Associated with aberrant p53 acetylation patterns that affect treatment response

  • In some contexts, promotes p53 acetylation to inhibit apoptosis (as in HCT116 cells)

Deacetylase Regulation:

• HDAC1/SIRT1 in Normal Cells:

  • Maintain low basal p53 acetylation under normal conditions

  • Respond to cellular signaling for controlled deacetylation

  • Create appropriate acetylation dynamics for normal p53 function

• HDAC1/SIRT1 in Cancer Cells:

  • Often overexpressed, leading to constitutive p53 deacetylation

  • May contribute to p53 inactivation in tumors with wild-type p53

  • Represent therapeutic targets for HDAC inhibitors to restore p53 function

Regulatory Complexes:

Normal cells maintain balanced acetyltransferase/deacetylase activities through protein complexes that include MDM2, which can recruit HDAC1 to p53. In cancer cells, this balance is frequently disrupted, either through MDM2 overexpression or through alterations in complex formation that affect p53 acetylation status .

Therapeutic Implications:

The differential regulation of K382 acetylation between normal and cancer cells provides a therapeutic window for interventions targeting acetylation machinery. HDAC inhibitors like depsipeptide have shown promise in restoring p53 acetylation at K382 and activating p53-dependent transcription programs in cancer cells . Understanding the cell type-specific regulation of K382 acetylation will be crucial for developing more targeted approaches that selectively affect cancer cells while sparing normal tissues.

What are emerging technologies for studying p53 K382 acetylation dynamics in live cells?

Recent technological advances have expanded our ability to study p53 K382 acetylation dynamics with unprecedented spatial and temporal resolution in living cells:

Real-time Imaging Approaches:

• FRET-based Acetylation Sensors:

  • Genetically encoded fluorescent biosensors containing p53 C-terminal domains

  • Conformational changes upon acetylation alter FRET efficiency

  • Enables real-time monitoring of K382 acetylation dynamics in living cells

  • Can reveal oscillatory patterns and single-cell heterogeneity

• Split Fluorescent Protein Systems:

  • One fragment fused to a K382 acetyl-lysine binding domain (e.g., bromodomain)

  • Complementary fragment fused to p53

  • Fluorescence reconstitution upon K382 acetylation

  • Allows spatial tracking of acetylated p53 populations within cells

Advanced Mass Spectrometry Applications:

• SILAC-based Temporal Analysis:

  • Stable isotope labeling with amino acids in cell culture

  • Enables quantitative comparison of acetylation levels across time points

  • Can be combined with subcellular fractionation to track acetylated p53 localization

• Targeted Parallel Reaction Monitoring (PRM):

  • Highly sensitive detection of specific acetylated peptides

  • Allows quantification of multiple p53 modifications simultaneously

  • Enables precise stoichiometry measurements of acetylation at different lysine residues

Genomic and Transcriptomic Integration:

• CUT&RUN with Acetyl-TP53 (K382) Antibody:

  • Cleavage Under Targets and Release Using Nuclease

  • Higher resolution alternative to ChIP for mapping genomic binding sites

  • Reveals genome-wide binding patterns of acetylated p53 with minimal background

• Nascent Transcriptomics:

  • Methods like SLAM-seq or TT-seq coupled with p53 acetylation status

  • Directly links K382 acetylation to immediate transcriptional outputs

  • Distinguishes primary from secondary transcriptional effects

These emerging technologies provide unprecedented insights into the spatiotemporal dynamics of p53 K382 acetylation and its relationship to p53 function. Integration of multiple approaches will be key to understanding how acetylation patterns translate into specific cellular responses and how these processes are dysregulated in disease states.

How might therapeutic targeting of p53 K382 acetylation be developed for cancer treatment?

Therapeutic strategies targeting p53 K382 acetylation represent a promising frontier in cancer treatment, potentially restoring p53 function in tumors with wild-type p53 and enhancing current treatment modalities:

Current Therapeutic Approaches:

• HDAC Inhibitors:

  • FDA-approved HDAC inhibitors (vorinostat, romidepsin) increase p53 K382 acetylation

  • Most effective in combination with DNA-damaging agents

  • Clinical limitation: lack of specificity for p53-related HDACs

• p300/CBP Activators:

  • Small molecules that enhance p300/CBP acetyltransferase activity

  • Potential to increase p53 K382 acetylation selectively

  • Still in preclinical development stages

Emerging Targeted Strategies:

• Selective HDAC Inhibition:

  • Development of isoform-specific HDAC inhibitors targeting those most involved in p53 deacetylation

  • Reduction of off-target effects seen with pan-HDAC inhibitors

  • Potential for greater efficacy and reduced toxicity

• Acetylation-Mimicking Approaches:

  • Peptides or small molecules that mimic acetylated K382 structure

  • Could disrupt interactions dependent on non-acetylated K382

  • May bypass need for actual acetylation in tumors with dysfunctional acetyltransferases

• Targeted Protein Degradation:

  • PROTAC (Proteolysis Targeting Chimera) technology targeting specific HDACs that deacetylate p53

  • More complete inhibition than catalytic inhibitors alone

  • Potential for greater specificity to p53-related complexes

Combination Therapy Rationales:

Cell Type Considerations:
The therapeutic targeting of p53 K382 acetylation needs to account for tissue-specific differences in acetylation effects. While increasing K382 acetylation promotes apoptosis in most cancer cells, it may have protective effects in neuronal cells . This differential response provides both challenges and opportunities for developing therapies with favorable therapeutic windows that spare normal tissues while effectively targeting cancer cells.

Future therapeutic developments will likely leverage our growing understanding of the context-dependent nature of p53 K382 acetylation to develop more personalized approaches based on tumor-specific acetylation patterns and regulatory mechanisms.

What are the key considerations when interpreting p53 K382 acetylation data in experimental and clinical contexts?

Interpreting p53 K382 acetylation data requires careful consideration of multiple factors that influence both the detection and functional significance of this modification:

Technical Interpretation Factors:

• Normalization and Quantification:

  • Always normalize acetylated p53 (K382) signal to total p53 levels

  • Consider the stoichiometry of acetylation (what percentage of total p53 is acetylated)

  • Acknowledge detection threshold limitations of antibody-based methods

• Temporal Dynamics:

  • Recognize that acetylation is a dynamic process with specific kinetics

  • Single time-point measurements may miss important temporal patterns

  • Consider the stability of the modification in your experimental system

• Contextual PTM Landscape:

  • Interpret K382 acetylation in the context of other p53 modifications

  • Acknowledge that modification patterns rather than single PTMs determine function

  • Consider potential antagonistic or synergistic relationships between modifications

Biological Context Considerations:

• Cell Type Specificity:

  • The same level of K382 acetylation may have different functional outcomes in different cell types

  • Neuronal cells show distinct responses compared to epithelial cancer cells

  • Compare results only between similar cell types or acknowledge limitations of cross-type comparisons

• Genetic Background Effects:

  • p53 mutation status fundamentally affects interpretation (acetylation of mutant vs. wild-type p53)

  • MDM2/MDMX levels modulate both p53 stability and acetylation

  • Consider status of relevant acetyltransferases and deacetylases

• Stress Context Dependency:

  • Different stressors induce distinct acetylation patterns and downstream effects

  • The same acetylation level may have different meanings depending on the triggering stress

  • Interpret acetylation in the context of the specific cellular stress response being studied

By systematically addressing these considerations when analyzing p53 K382 acetylation data, researchers can develop more nuanced and accurate interpretations that account for the complex and context-dependent nature of p53 regulation through acetylation.

What are the most significant unanswered questions regarding p53 K382 acetylation in cellular function and disease?

Despite significant advances in understanding p53 K382 acetylation, several critical questions remain unanswered, presenting important opportunities for future research:

Mechanistic Questions:

• Acetylation Reader Mechanisms:

  • Which specific proteins recognize acetylated K382 to mediate downstream effects?

  • How do these readers distinguish K382 acetylation from acetylation at other p53 lysine residues?

  • What is the structural basis for acetylation-dependent protein-protein interactions?

• Regulatory Selectivity:

  • What determines which specific lysine residues get acetylated under different stress conditions?

  • How is acetyltransferase specificity regulated to target K382 versus other lysines?

  • What controls the balance between competing modifications (acetylation vs. ubiquitination vs. methylation) at K382?

Functional Questions:

• Target Gene Selectivity:

  • How does K382 acetylation influence p53's binding to specific response elements?

  • What determines whether K382 acetylation promotes cell cycle arrest versus apoptotic gene programs?

  • How does the effect of K382 acetylation on gene expression differ between cell types?

• Non-transcriptional Functions:

  • Does K382 acetylation affect p53's direct interactions with mitochondria and apoptotic machinery?

  • How does acetylation influence p53's roles in metabolism and autophagy?

  • Are there cytoplasmic functions of p53 that are regulated by K382 acetylation?

Clinical and Translational Questions:

• Biomarker Potential:

  • Can p53 K382 acetylation status serve as a predictive biomarker for treatment response?

  • How does K382 acetylation status correlate with patient outcomes in different cancer types?

  • What are the technical challenges in measuring K382 acetylation in patient samples?

• Therapeutic Targeting:

  • How can we develop approaches that specifically target p53 K382 acetylation without affecting global acetylation?

  • What combination therapy strategies might be most effective in leveraging p53 K382 acetylation for cancer treatment?

  • How can we account for and exploit cell type-specific differences in p53 acetylation responses?

• Beyond Cancer:

  • What role does p53 K382 acetylation play in aging and age-related diseases?

  • How does K382 acetylation contribute to p53's functions in metabolism, fertility, and development?

  • Is there therapeutic potential in modulating p53 K382 acetylation in non-cancer conditions?